Denali Therapeutics Inc
For the period ended Dec 31, 2023. Filed Feb 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 28, 2024
DNLI$20.33+1.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(In thousands, except share amounts)
| December 31, 2023 | December 31, 2022 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $127,106 | $218,044 |
| Short-term marketable securities | 907,405 | 1,118,171 |
| Prepaid expenses and other current assets | 29,626 | 36,104 |
| Total current assets | 1,064,137 | 1,372,319 |
| Property and equipment, net | 45,589 | 44,087 |
| Operating lease right-of-use asset | 26,048 | 30,437 |
| Other non-current assets | 18,143 | 13,399 |
| Total assets | $1,153,917 | $1,460,242 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $9,483 | $2,790 |
| Cost sharing payments due to related party | — | 4,388 |
| Accrued expenses and other current liabilities | 68,499 | 66,691 |
| Related party contract liability, current | — | 290,053 |
| Total current liabilities | 77,982 | 363,922 |
| Related party contract liability, less current portion | — | 479 |
| Operating lease liability, less current portion | 44,981 | 53,032 |
| Other non-current liabilities | — | 379 |
| Total liabilities | 122,963 | 417,812 |
| Commitments and contingencies (Note 8) | ||
| Stockholders’ equity: | ||
| Convertible preferred stock, $0.01 par value; 40,000,000 shares authorized as of December 31, 2023 and December 31, 2022; 0 shares issued and outstanding as of December 31, 2023 and December 31, 2022 | — | — |
| Common stock, $0.01 par value; 400,000,000 shares authorized as of December 31, 2023 and December 31, 2022; 138,385,498 and 135,965,918 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively | 1,711 | 1,686 |
| Additional paid-in capital | 2,144,811 | 2,018,617 |
| Accumulated other comprehensive income (loss) | 643 | (6,886) |
| Accumulated deficit | (1,116,211) | (970,987) |
| Total stockholders’ equity | 1,030,954 | 1,042,430 |
| Total liabilities and stockholders’ equity | $1,153,917 | $1,460,242 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.